Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women (NCT00539162)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical research study is to find out if combining a standard blood test (CA-125) that checks for ovarian cancer with other blood tests that check for related tumor markers may be helpful in the early detection of ovarian cancer in women who are at low risk. Tumor markers are substances in the blood that may be related to ovarian cancer.
Who can join: Review the eligibility criteria below.
Location: Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine — Miami, Florida
Age range: 50 Years to 74 Years
🧪 Interventions in This Study
- Questionnaire (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine — Miami, Florida
- John Stoddard Cancer Center — Des Moines, Iowa
- University of Minnesota — Minneapolis, Minnesota
- Carol G. Simon Cancer Center / Atlantic Health — Morristown, New Jersey
- University of Rochester Medical Center — Rochester, New York
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
- Women's and Infant's Hospital — Providence, Rhode Island
- The University of Texas at Austin — Austin, Texas
- University of Texas (UT) Southwestern Medical Center — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Women's Hospital of Texas, Obstetrics and Gynecology Associates (OGA) — Houston, Texas
- UT Health Science Center San Antonio — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (713) 563-1790
Email: gcorriga@mdanderson.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.